The cannabis industry stands at a historic inflection point. With the December 18, 2025, Executive Order directing the Department of Justice to expedite the rescheduling of cannabis to Schedule III, operators are preparing for a seismic shift in federal tax liability and regulatory oversight. However, this federal momentum does not erase the intricate, highly localized compliance burdens that dictate day-to-day operations.

What Are You Looking to Do?

Whether you are a multi-state operator expanding into a new limited-license market or a startup cultivator drafting your first standard operating procedures, success requires deterministic execution. Select your primary objective below to access our specialized knowledge base.

The Shifting Federal Landscape: Schedule III & Executive Orders

For decades, cannabis has been classified as a Schedule I controlled substance under the Controlled Substances Act (CSA), placing it in the same category as heroin and creating insurmountable barriers to standard business operations. The most punitive of these barriers is Internal Revenue Code (IRC) Section 280E, which prohibits businesses trafficking in Schedule I or II substances from deducting ordinary and necessary business expenses. Under 280E, cannabis operators can only deduct the Cost of Goods Sold (COGS), resulting in effective federal tax rates that frequently exceed 70 percent.

The regulatory environment shifted dramatically on December 18, 2025, when President Trump signed an Executive Order instructing the Attorney General and the Drug Enforcement Administration (DEA) to expedite the final rulemaking process to reclassify cannabis as a Schedule III substance. This directive builds upon the Department of Health and Human Services' (HHS) 2023 scientific recommendation and effectively bypasses the administrative delays that stalled the DEA's January 2025 hearings.

Moving cannabis to Schedule III fundamentally alters the financial viability of the industry. Because IRC 280E only applies to Schedule I and II substances, a finalized Schedule III designation removes this crushing tax burden. Cannabis dispensaries, cultivators, and processors will finally be permitted to claim standard business deductions under IRC Section 162, including payroll, commercial rent, marketing, and administrative overhead. However, Schedule III is not federal legalization. State-level regulatory frameworks, FDA oversight, and stringent Department of Transportation (DOT) drug testing mandates for safety-sensitive roles remain fully intact. Operators must proactively restructure their tax strategies and corporate entities now to capitalize on the impending rule change.

State-by-State Regulatory Guides

Federal rescheduling does not preempt state law. The cannabis industry remains a patchwork of highly localized, heavily regulated markets. Securing a state license is only half the battle; operators must also navigate the "dual-licensing hurdle," securing local municipal authorization - such as conditional use permits and CEQA compliance in California - before state regulators will issue an active license.

Essential Legal Frameworks

Beyond state licensing, cannabis businesses face unique legal hurdles that require specialized corporate structuring and risk mitigation strategies. Standard boilerplate contracts and traditional business practices frequently fail when applied to the cannabis sector due to the lingering threat of federal forfeiture and the lack of bankruptcy protection.

Federal Law Warning: The cannabis industry remains subject to federal prohibition under the Controlled Substances Act. State legalization does not preempt federal enforcement. The content provided on this website is for educational purposes only and does not constitute legal advice.